To include your compound in the COVID-19 Resource Center, submit it here.

No ripple effect

Why a Japanese generics and biosimilars deal had no effect on Japan's biotechs

In contrast to big swings that occur on innovator partnering news, BioCentury's equal price-weighted index of 34 Japanese biotechs did precious little after Nichi-Iko Pharmaceutical Co. Ltd. (Tokyo:4541) announced plans to acquire fellow generics and

Read the full 359 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers